期刊文献+

终末期肝病模型评分对预测2型肝肾综合征患者预后的意义 被引量:6

Significance of MELD Score on the Prognosis for Patients with Type 2 Hepatorenal Syndrome
暂未订购
导出
摘要 目的探讨终末期肝病模型(MELD)评分对预测2型肝肾综合征(HRS)患者预后的意义。方法以台州市中心医院100例2型HRS患者为研究对象。记录患者的肝肾功能、电解质、凝血功能、血常规、治疗方法和转归,计算MELD评分。自确诊之日起,随访3个月。随访期间死亡患者被纳入死亡组,存活患者纳入存活组。应用多元回归分析探讨2型HRS患者预后的影响因素。结果 (1)死亡组患者血肌酐、尿素氮、总胆红素水平及MELD值均显著高于存活组,差异均有统计学意义(P<0.05);而两组在年龄、性别构成、脑病、消化道出血、脓毒症、丙氨酸氨基转移酶(ALT)、清蛋白、尿酸、白细胞计数、血红蛋白水平、血小板计数、国际标准化比率(INR)和C反应蛋白(CRP)方面比较,差异均无统计学意义(P>0.05)。(2)多元回归分析显示,MELD每升高1个单位,死亡风险增加33.8%;总胆红素每升高1个单位,死亡风险增加20.5%;血肌酐每升高1个单位,死亡风险增加18.5%。结论 MELD评分可预测2型HRS患者3个月内的死亡风险。 Objective To explore the significance of the end-stage liver disease(MELD) scores on the prognosis of patients with type 2 hepatorenal syndrome(HRS). Methods 100 patients with type 2 HRS from Taizhou Central Hospital were involved into the study.Liver and kidney function,electrolyte,coagulation function,blood routines,treatment and sequelae were recorded and MELD score were calculated.All the patients were followed up for three months after confirmation of the disease.Those who died during following up were categorized into death group,while those who survived into survival group.Multiple regression analysis was used to analyze the influencing factors for the prognosis of type 2 HRS patients. Results(1) Patients in the death group had significantly higher levels of creatinine,urea nitrogen and total bilirubin and a higher MELD value compared with survival group(P0.05).While the differences between the two groups in age and sex structures,encephalopathia,bleeding of the gastro intestinal tract,pyemia,ALT,albumin,uric acid,white blood cell count,hemoglobin level,platelet count,INR and CRP were not statistically significant(P0.05).(2) Multiple regression analysis showed that mortality risk would increase by 33.8% when MELD increased by one unit;mortality risk would increase by 20.5% when total bilirubin increased by one unit;mortality risk would increase by 18.5% when creatinine increased by one unit. Conclusion MELD score can predict mortality risk within three months in patients with type 2 HRS.
出处 《中国全科医学》 CAS CSCD 北大核心 2012年第7期759-761,共3页 Chinese General Practice
关键词 肝肾综合征 终末期肝病模型 预后 Hepatorenal syndrome Model for end-stage liver disease Prognosis
  • 相关文献

参考文献7

  • 1陈玲玲,陈霞,颜海帆,毛君梁,陈振华.影响1型肝肾综合征患者预后因素的临床研究[J].中国中西医结合肾病杂志,2011,12(6):513-515. 被引量:2
  • 2Salerno F,Gerbes A,Gines P,et al.Diagnosis,prevention and treat-ment of hepatorenal syndrome in cirrhosis[J].Gut,2007,56(9):1310.
  • 3Schepke M,Appenrodt B,Heller J,et al.Prognostic factors for pa-tients with cirrhosis and kidney dysfunction in the era of MELD:results of a prospective study[J].Liver Int,2006,26:834-839.
  • 4Alessandria C,Ozdogan O,Guevara M,et al.MELD score and clinical type predict prognosis in hepatorenal syndrome:relevance to liver trans-plantation[J].Hepatology,2004,41:1282-1289.
  • 5严颖,麦丽,林炳亮,江元森,赵志新,高志良.肝肾综合征121例COX生存分析[J].中山大学学报(医学科学版),2006,27(B04):183-185. 被引量:4
  • 6张曙光,阮长乐,于振海,李光新,李兆亭.断流和分流联合术治疗肝硬化门静脉高压症疗效观察[J].中国实用外科杂志,2001,21(3):147-148. 被引量:33
  • 7Alessandria C,Ozdogan O,Guevara M,et al.MELD score and clinical type predict prognosis in hepatorenal syndrome:relevance to liver trans-plantation[J].Hepatology,2005,41(6):1282-1289.

二级参考文献17

  • 1庄鹏,江元森,李学俊,谢俊强,邓友,张绍全,姚集鲁.血液滤过透析联合血浆置换治疗中晚期慢性重型肝炎的临床研究[J].中国血液净化,2002,1(8):27-29. 被引量:11
  • 2刘瑾琨,谭毓铨.门静脉高压症联合手术前后血流动力学的改变[J].中华外科杂志,1993,31(4):203-206. 被引量:50
  • 3Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrho-.
  • 4Schepke M, Appenrodt B, Heller J, et al. Prognostic factors for patients with cirrhosis and kidney dysfunction in the era of MELD : results of a prospective study. Liver Int, 2006,26 ( 3 ) : 834 - 839.
  • 5Mitzner S, Klammt S, Stange J, et al. Albumin regeneration in liv- er support - comparison of different methods. Ther Apher Dial, 2006,10(2) :108 - 117.
  • 6Alessandria C, Ozdogan O, Guevara M, et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: rele- vance to liver transplantation. Hepatology, 2004,41 ( 6 ) : 1282 - 1289.
  • 7Sundaram V, A1 - Osaimi AM, Lewis JJ, et al. Severe prolonga- tion of the INR in spur cell anemia of cirrhosis : true : true and related ? Dig Dis Sci. 2006,51 (7) : 1203 - 1205.
  • 8Bambha K, Kim WR, Kremers WK, et al. Predicting survival a- mong patients listed for liver transplantation: an assessment of erial MELD measurements. Am J Transplant, 2004, 4 ( 11 ) :1798 - 1804.
  • 9Huo TI, Wu JC, Lin HC, et al. Evaluation of the increase in mod- el for end - stage liver disease ( Delta MELD) score over time as a prognostic predictor in patients with advanced cirrhosis: risk factor analysis and comparison with initial MELD and Child - Turnotte - Push scnre. 1 Henato1.2005.42 ( 7 ) :826 - 832.
  • 10Merion RM, Wolfe RA, Dykstra DM, et al. Longitudinal assess- ment of mortality risk among candidates for liver transplantation. Liver Transplant,2003,9 ( 1 ) : 12 - 18.

共引文献36

同被引文献66

  • 1沈美龙,徐洪涛,邢同京,咸建春,韩立彬,王开林,李浩.终末期肝病模型联合白细胞介素15评分对慢性乙型肝炎预后预测[J].中华临床医师杂志(电子版),2011,5(21):6358-6362. 被引量:4
  • 2Sheng, Qin-Song,Lang, Ren,He, Qiang,Yang, Yong-Jiu,Zhao, De-Fang,Chen, Da-Zhi.Indocyanine green clearance test and model for end-stage liver disease score of patients with liver cirrhosis[J].Hepatobiliary & Pancreatic Diseases International,2009,8(1):46-49. 被引量:36
  • 3Salerno F, Gerbes A, nosis, prevention and syndrome in cirrhosis (9): 1310 -1318. Ginbs P, et al. Diag- treatment of hepatorenal [ J]. Gut, 2007, 56.
  • 4Schrier RW, Shchekochikhin D, Gin6s P. Renal failure in cirrhosis: prerenal azotemia, hepatorenal syndrome and acute tubular necrosis[J]. Nephrol Dial Transplant, 2012, 27(7): 2625-2628.
  • 5Donadio C. Effect of glomerular filtration rate impairment on diagnostic performance of neutrophil gelafinase-associated lipocalin and B-type natriuretic peptide as markers of acute cardiac and renal failure in chronic kidney disease patients[J]. Crit Care, 2014, 18(1): R39.
  • 6Verna EC, Brown RS, Farrand E, et al. Urinary neutrophil gelatinase- associated lipocalin predicts mortality and identifies acute kidney injury in cirrhosis[J]. Dig Dis Sei, 2012, 57(9): 2362-2370.
  • 7Gungor G, Ataseven H, Demir A, et al. Neutrophil gelatinase- associated lipocalin in prediction of mortality in patients with hepatorenal syndrome: a prospective observational study[J]. Liver Int, 2014, 34(1): 49-57.
  • 8European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis[J]. J Hepatol, 2010, 53(3): 397-417.
  • 9Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices[J]. Br J Surg, 1973, 60(8): 646-649.
  • 10Karnath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease[J]. Hepatology, 2001, 33(2): 464-470.

引证文献6

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部